NCT03520686 2026-04-15
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
Clinical Trials
33 trialsNCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT06448364 2024-11-06
LTbR
Pfizer
Phase 1 Terminated
NCT00998166 2024-07-30
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
Columbia University
Phase 2 Terminated
NCT04099836 2023-12-26
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Duke University
Phase 2 Terminated
NCT03713944 2023-03-01
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT00960297 2021-12-06
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00438204 2021-04-13
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02162537 2019-02-01
METAL2
Centre Hospitalier Intercommunal Creteil
Phase 3 Terminated
NCT01578551 2018-12-19
Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00924209 2018-11-30
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00955305 2018-06-06
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01090830 2018-02-23
HCH003
Holy Cross Hospital, Florida
Phase 1/2 Terminated
NCT00369070 2018-01-04
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
Amgen
Phase 2 Terminated
NCT00932152 2017-10-19
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00728845 2017-05-23
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT00351039 2017-03-23
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT00702572 2016-09-22
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT00404703 2016-08-24
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00766246 2016-04-19
Phase II Avastin Trial for Stage IIIB/IV NSCLC
Pharmatech
Phase 2 Terminated
NCT00850577 2015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT00749567 2015-09-28
Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT02179567 2015-09-28
Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01507740 2015-04-29
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Medical University Innsbruck
Terminated
NCT00976677 2014-05-30
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00369551 2014-03-06
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00334763 2012-07-10
Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
Northwestern University
Phase 2 Terminated
NCT00293332 2011-02-09
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
University of California, San Francisco
Phase 2 Terminated
NCT00378573 2010-01-26
Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sanofi
Phase 2 Terminated
NCT00313768 2009-09-28
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
Pfizer
Phase 2 Terminated
NCT00434226 2009-08-21
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Genentech, Inc.
Phase 2 Terminated